Ключевые слова
Как цитировать
Аннотация
Выяснение патогенетических особенностей злокачественных новообразований, ассоциированных с метаболическим синдромом (МС) представляет актуальность вследствие значительной распространенности таких опухолей. Исследования механизмов вовлеченности компонентов МС в патогенез рака целесообразно дополнить изучением ряда транскрипционных и ростовых факторов, ассоциированных с энергетических дисбалансом клетки и вовлеченных в процессы пролиферации, апоптоза, ангиогенеза, клеточной подвижности и воспаления. Необходимы дополнительные исследования с целью выявления наиболее перспективных молекулярных мишеней для таргетной терапии злокачественных новообразований, ассоциированных с МС, с целью увеличения продолжительности и качества жизни данной категории больных.
Библиографические ссылки
Берштейн, Л.М. Онкоэндокринология. Традиции, современность и перспективы / Л.М. Берштейн. - СПб.: Наука, 2004. - 343 с.
Берштейн Л.М., Евтушенко Т.П., Цырлина Е.В. и др. Сравнительное изучение пяти- и десятилетних результатов метаболической реабилитации онкологических больных. В кн.: Нейроэндокринная система, метаболизм, иммунитет и рак (ред. К.П. Хансон, В.М. Дильман). - СПб., 1992. - С. 102-112.
Биологические маркеры опухолей: фундаментальные и клинические исследования / Под ред. Н.Е. Кушлинского, М.А. Красильникова. - М.: Издательство РАМН, 2017. - 632 с.
Бочкарева Н.В., Коломиец Л.А., Кондакова И.В. Сочетание гиперплазии и рака эндометрия с миомой матки: роль половых гормонов, их рецепторов и ферментов метаболизма эстрогенов // Вопросы онкологии. - 2005. - Т 51. - № 4. - С. 427-433.
Коломиец Л.А., Бочкарева Н.В., Чернышева А.Л. Рак эндометрия и метаболический синдром. - Томск: Типография «Иван Федоров», 2010. - 228 с.
Кручинина М.В., Курилович С.А., Громов А.А. и др. Кардиометаболические факторы и колоректальный рак // Атеросклероз. - 2016. - Т. 12. - № 1. - C. 46-60.
Любота Р.В. Применение метформина в лечении рака молочной железы у больных с метаболическим синдромом // Опухоли женской репродуктивной системы. - 2015. - № 4. - C. 18-24.
Alshaker H., Sacco K., Alfraidi A. et al. Leptin signalling, obesity and prostate cancer: molecular and clinical perspective on the old dilemma // Oncotarget. - 2015. - Vol. 6. - № 34. - P. 35556-35563.
Azhar S. Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease // Future Cardiol. - 2010. - Vol. 6. № 5. - P. 657-691.
Berstein L.M. Modern approach to metabolic rehabilitation of cancer patients: biguanides (phenformin and metformin) and beyond // Future Oncology. - Vol. 6. - № 8. - P. 1313-1323.
Catalano S., Mauro L., Marsico S. et al. Leptin induces, via ERK1/ERK2 signal, functional activation of estrogen receptor alpha in MCF-7 cells // J. Biol. Chem. - 2004. - Vol. 279. - № 19. - P. 19908-19915.
Chia P.-P., Fan S.-H., Say Y-H. Screening of peroxisome proliferator-activated receptors (PPARs) a, у and ß gene polymorphisms for obesity and metabolic syndrome association in the multi-ethnic Malaysian population // Ethn. Dis. - 2015. - Vol. 25. - № 4. - P. 383-390.
Cowey S., Hardy R.W. The metabolic syndrome a high-risk state for cancer? // Am. J. of Pathology. - 2006. - Vol. 169. - № 5. - P. 1505-1522.
Dekker M.J., Su Q., Baker C. et al. Fructose: a highly lipogenic nutrient implicated in insulin resistance, hepatic steatosis, and the metabolic syndrome // Am. J. Physiol. Endocrinol. Metab. - 2010. - Vol. 299. - № 5. - E685-694.
Ding J., Li C., Tang J. et al. Higher expression of proteins in IGF/IR axes in colorectal cancer is associated with type 2 diabetes mellitus // Pathol. Oncol. Res. - 2016. - Vol.22. - № 4. - P. 773-779.
Esposito K., Chiodini P., Colao A. et al. Metabolic syndrome and risk of cancer: a system review and meta-analysis // Diabetes Care. - 2012. - Vol. 35. - P. 2402-2411.
Gao J., Tian J., Lv Y. et al. Leptin induces functional activation of cyclooxygenase-2 through JAK2/STAT3, MAPK/ERK, and PI3K/AKT pathways in human endometrial cancer cells // Cancer Sci. - 2009. - Vol. 100. - № 3. - P. 389-395.
Guigas B., Viollet B. Targeting AMPK: from ancient drugs to new small-molecule activators // EXS. - 2016. - Vol. 107. - P. 327-350.
Grisouard J., Dembinski K., Mayer D. et al. AMP-activated protein kinase in adipocytes to modulate obesity-related adipokine production associated with insulin resistance and breast cancer cell proliferation // Diabetol Metab Syndr. - 2011. - Vol. 20. - P. 16. - DOI: 10.1186/1758-5996-3-16
Karnati H.K., Panigrahi M.K., Li Y. et al. Adiponectin as a potential therapeutic target for prostate cancer // Curr. Pharm. Des. - 2017. - DOI: 10.2174/1381612823666170208123553
Kato S., Abarzua-Catalan L., Trigo C. et al. Leptin stimulates migration and invasion and maintains cancer stemlike properties in ovarian cancer cells: an explanation for poor outcomes in obese women // Oncotarget. - 2015. - Vol. 6. - № 25. - P. 21100-21119.
Kim J., Yang G., Kim Y. et al. AMPK activators: mechanisms of action and physiological activities // Exp. Mol. Med. - 2016. - Vol. 48. - № 4. - e224.
Kim A.Y. Lee Y.S., Kim K.H. et al. Adiponectin represses colon cancer cell proliferation via AdipoR1- and -R2-mediated AMPK activation // Mol. Endocrinol. - 2010. - Vol. 24. - № 7. - P. 1441-1452.
Ko S., Yoon S.J., Kim D. et al. Metabolic risk profile and cancer in Korean men and women // J. Prev. Med. Public Health. - 2016. - Vol. 49. - № 3. - P. 143-152.
Koda M., Sulkowska M., Wincewicz A. et al. Expression of leptin, leptin receptor, and hypoxia-inducible factor 1 alpha in human endometrial cancer // Ann N Y Acad Sci.-2007. - Vol. 1095. - P. 90-98.
Lagana A.S., Vitale S.G., Nigro A. et al. Pleiotropic action of peroxisome proliferator-activated receptors (PPARs) in dysregulated metabolic homeostasis, inflammation and cancer: current evidence and future perspectives // International J. of Molecular Science. - 2016. - Vol. 17. - № 7. - pii: E999. - DOI: 10.3390/ijms17070999
Lai L., Wang M., Martin O.J. et al. A role for peroxisome proliferator-activated receptor у coactivator 1 (PGC-1) in the regulation of cardiac mitochondrial phospholipid biosynthesis // J. Biol. Chem. - 2014. - Vol. 289. - № 4. - P. 2250-2259.
Li L., Zhao Z., Xia J. et al. A Long-term high-fat/high-su-crose diet promotes kidney lipid deposition and causes apoptosis and glomerular hypertrophy in Bama minipigs // PLoS One. - 2015. - Vol. 10. - № 11. - e0142884. - DOI: 10.1371/journal.pone.0142884
Liu N., Zhao J., Wang J. et al. Farnesoid X receptor ligand CDCA suppresses human prostate cancer cells growth by inhibiting lipid metabolism via targeting sterol response element binding protein 1 // Am. J. Transl. Res. - 2016. - Vol. 8. - № 11. - P. 5118-5124.
Liu C.Y., Su J.C., Huang T.T. et al. Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells // Mol. Oncol. - 2017. - Vol.11. - № 3. - P. 266-279.
Malih S, Najafi R. AdipoRon: a possible drug for colorectal cancer prevention? // Tumour Biol. - 2015. - Vol. 36. - № 9. - P. 6673-6675.
Mauro L., Pellegrino M., De Amicis F., et. al. Evidence that estrogen receptor a interferes with adiponectin effects on breast cancer cell growth // Cell Cycle. - 2015. - Vol. 13. - P. 553-554.
McCormack D., Schneider J., McDonald D., McFadden D. The antiproliferative effects of pterostilbene on breast cancer in vitro are via inhibition of constitutive and leptin-induced Janus kinase/signal transducer and activator of transcription activation // Am. J. Surg. - 2011. - Vol. 202. - № 5. - P. 541-544.
Merino V.F., Cho S., Liang X. et al. Inhibitors of STAT3, ß-catenin, and IGF-1R sensitize mouse PIK3CA-mu-tant breast cancer to PI3K inhibitors // Mol. Oncol. - 2017. - DOI: 10.1002/1878-0261.12053
Moreno-Arriola E., El Hafidi M., Ortega-Cuéllar D. et al. AMP-activated protein kinase regulates oxidative metabolism in Caenorhabditis elegans through the NHR-49 and MDT-15 transcriptional regulators // PLoS One. - 2016. - Vol.11. - № 1. - e0148089. - DOI: 10.1371/journal.pone.0148089
Nambiar D.K., Deep G., Singh R.P. et al. Silibinin inhibits aberrant lipid metabolism, proliferation and emergence of an-drogen-independence in prostate cancer cells via primarily targeting the sterol response element binding protein 1 // Oncotarget. - 2014. - Vol. 5. - № 20. - P. 10017-10033.
Nejati-Koshki K., Akbarzadeh A., Pourhasan-Moghaddam M. et al. Inhibition of leptin and leptin receptor gene expression by silibinin-curcumin combination // Asian Pac. J. Cancer Prev. - 2014. - Vol. 14. - № 11. - P. 6595-6599.
Ogunwobi O.O., Beales I.L. The anti-apoptotic and growth stimulatory action of leptin in human colon cancer cells involves activation of JNK mitogen activated protein kinase JAK2 and PI3 kinase/Akt // Int. J. Colorectal Dis. - 2007. - Vol. 22. - № 4. - P. 401-409.
Odate S., Veschi V., Yan S. et al. Inhibition of STAT3 with the generation 2.5 antisense oligonucleotide, AZD9150, decreases neuroblastoma tumorigenicity and increases chemosensitivity // Сiiп. Cancer Res. - 2017. - Vol. 23. - № 7. - P. 1771-1784.
Osaki Y. Taniguchi S., Tahara A. et al. Metabolic syndrome and incidence of liver and breast cancers in Japan // Cancer Epidemiol. - 2012. - Vol. 36. - № 2. - P. 141-147.
Rosato V., Zucchetto A., Bosetti C. et al. Metabolic syndrome and endometrial cancer risk // Annals of Oncology. - 2011. - Vol. 22. - P. 884-889.
Ruiz R., Jideonwo V., Ahn M. et al. Sterol regulatory element-binding protein-1 (SREBP-1) is required to regulate glycogen synthesis and gluconeogenic gene expression in mouse liver //J. Biol. Chem. - 2014. - Vol. 289. - № 9. - P. 5510-5517.
Saengboonmee C., Seubwai W., Cha'on U. et al. Metformin exerts antiproliferative and anti-metastatic effects against cholangiocarcinoma cells by targeting STAT3 and NF-kB //Anticancer Res. - 2017. - Vol. 37. - № 1. - P. 115-123.
Samani A.A., Yakar S., Leroith D. et al. The role of the IGF system in cancer growth and metastasis: overview and recent insight //Endocrine Reviews. - 2007. - Vol. 28. - № 1. - P. 20-47.
Scheithauer T.P., Dallinga-Thie G.M., de Vos W.M. et al. Causality of small and large intestinal microbiota in weight regulation and insulin resistance // Mol. Metab. - 2016. - Vol. 5. - № 9. - P.759-770.
Sharma D., Saxena N.K., Vertino P.M., Anania F.A. Leptin promotes the proliferative response and invasiveness in human endometrial cancer cells by activating multiple signal-transduction pathways // Endocr. Relat. Cancer. - 2006. - Vol. 13. - № 2. - P. 629-640.
Shebl F.M., Andreotti G., Meyer T.E. et al. Metabolic syndrome and insulin resistance in relation to biliary tract cancer and stone risks: a population-based study in Shanghai, China // Br. J. Cancer. - 2011. - Vol. 105. - № 9. - P. 1424-1429.
Spirina L.V., Bochkareva N.V., Kondakova I.V. et al. Regulation of insulin-like growth NF-kB proteasome system in endometrial cancer // Molecular Biology. - 2012. - Vol. 46. - № 3. - P. 407-413.
Spirina L.V., Yunusova N.V., Kondakova I.V. et al. Association of growth factors, HIF-1 and NF-kB expression with proteasome in endometrial cancer // Molecular Biology Reports. - 2012. - Vol. 39. - № 9. - P. 8655-8662.
Sugiyama M., Takahashi H., Hosono K. et al. Adiponectin inhibits colorectal cancer cell growth through the AMPK/ mTOR pathway // Int. J. Oncol. - 2009. - Vol. 34. - № 2. - P. 339-344.
Tae C.H., Kim S.E., Jung S.A., et al. Involvement of adiponectin in early stage of colorectal carcinogenesis // BMC Cancer.-2014, 14, 811. DOI: 10.1186/1471-2407-14-811
Wen S., Niu Y., Lee S.O. et al. Targeting fatty acid synthase with ASC-J9 suppresses proliferation and invasion of prostate cancer cells // Mol Carcinog. - 2016. - Vol. 55. - № 12. - P. 2278-2290.
Wu X., Yan Q., Zhang Z. et al. Acrp30 inhibits leptin-induced metastasis by downregulating the JAK/STAT3 pathway via AMPK activation in aggressive SPEC-2 endometrial cancer cells // Oncol. Rep. - 2012. - Vol. 27. - № 5. - P. 1488-1496.
Wu C.Y., Yang Y.H., Lin Y.Y. et al. Anti-cancer effect of danshen and dihydroisotanshinone I on prostate cancer: targeting the crosstalk between macrophages and cancer cells via inhibition of the STAT3/CCL2 signaling pathway // Oncotarget. - 2017. - DOI: 10.18632/oncotarget.14958
Yunusova N.V., Spirina L.V., Kondakova I.V. et al. Relationship between the expression levels of PAPP-A metalloproteinase and growth and transcriptional factors in endometrial cancer // Biology Bulletin. - 2013. - Vol. 40. - № 3. - P. 253-259.
Yunusova N.V., Spirina L.V., Frolova A.E. et al. Association of IGFBP-6 expression with metabolic syndrome and adipo-nectin and IGF-IR receptor levels in colorectal cancer // Asian Pac. J. of Cancer Prev. - 2016. - Vol. 17. - № 8. - P. 3961-3967.
Yunusova N.V., Villert A.B., Spirina L.V. et al. Insulin-like growth factors and their binding proteins in tumor and ascites of ovarian cancer patients: association with response to neoadjuvant chemotherapy //Asian Pac. J. Cancer Prev. - 2016. - Vol. 17. - № 12. - P. 6215-6219.
Zhao Y.-y., Guo L., Zhao X-y. et al. Transcriptional activation of insulin-like growth factor binding protein 6 by 17ß-estradiuol in SaOS-2 cells // Exp. Mol. Med. - 2009. - Vol. 41. - № 7. - P. 478-486.
Zhang H., Yee D. Is the type I insulin-like growth factor receptor a therapeutic target in endometrial cancer? // Clinical Cancer Research. - 2006. - Vol. 12. - P. 6323-6325.
Zhou J-R., Blackburn G.L., Walker W.A. Symposium introduction: metabolic syndrome and the onset of cancer // Am. J. Clin. Nutr. - 2007. - Vol. 86. - № 3. - P. 817S-819S.
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.
© АННМО «Вопросы онкологии», Copyright (c) 2017